Skip to main content

Dave Muoio

By Dave Muoio | 02:52 pm | April 25, 2018
An analysis of Doctor On Demand administrative data conducted by the RAND Corporation suggests that patients turning to direct-to-consumer telemedicine services in the days following natural disasters such as hurricanes are most often seeking routine care and guidance, as opposed to treatment for new issues prompted by the storms.
By Dave Muoio | 11:22 am | April 25, 2018
San Francisco-based telemedicine provider Doctor On Demand announced today the closure of a $74 million round of Series C financing.
By Dave Muoio | 03:45 pm | April 24, 2018
Today, remote clinical trial company Science 37 and diagnostic clinical decision support system maker VisualDx have announced an effort to jointly engage patients and clinicians in their respective networks.
By Dave Muoio | 11:30 am | April 24, 2018
Today, Bothell, Washington-based Steth IO announced the launch of its smartphone-based digital stethoscope.
By Dave Muoio | 04:32 pm | April 23, 2018
Researchers from the University of California San Diego have developed a low-cost, single-use tattoo-like wearable that measures the user’s glucose levels.
By Dave Muoio | 01:16 pm | April 23, 2018
The mere mention of doctors and needles frequently can leave children in terror, and oftentimes the promise of a lollipop won’t be enough to calm their fears.
By Dave Muoio | 04:45 pm | April 20, 2018
Data published in Scientific Reports describes an algorithm that allows users to measure a patient’s pulse wave velocity using the camera on a smartphone.
By Dave Muoio | 04:42 pm | April 19, 2018
RapidSOS, a five-year-old startup focused on updating emergency response systems with data-driven technology, has raised $16 million in funding from Highland Capital, Microsoft Ventures, and CSAA Insurance Group, according to a statement.
By Dave Muoio | 02:28 pm | April 19, 2018
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
By Dave Muoio | 10:40 am | April 19, 2018
New York City-based digital consult platform RubiconMD has closed a $13.